Phase 2a study of rencofilstat for the treatment of hepatocellular carcinoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Sep 2022 According to a Hepion Pharmaceuticals media release, Chief Medical Officer, Todd Hobbs, MD, will participate in the Novel Targets in Oncology: Risk vs. Reward panel at the Cantor Oncology, Hematology & HemeOnc Conference and focus his discussion on this trial.
27 May 2022 According to a Hepion Pharmaceuticals media release, initiation of screening and enrollment is expected to begin in the third quarter of 2022.
27 May 2022 According to a Hepion Pharmaceuticals media release, this trial presented at the 5th Global NASH Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com